Tagrisso + Orpathys Hits Primary Endpoint in 1st-Line EGFRm Lung Cancer
AZN is trading near its 52-week low of $146.1 (10% above the low).
Summary
AstraZeneca's SANOVO Phase III trial showed Tagrisso plus Orpathys significantly improved progression-free survival versus Tagrisso alone in 1st-line EGFR-mutated NSCLC with MET overexpression, with encouraging overall survival trends.
Key Events · Product Development and Regulatory · AZN
-
SANOVO Trial Meets Primary Endpoint
Tagrisso plus Orpathys demonstrated statistically significant and highly clinically meaningful PFS improvement versus Tagrisso alone in 1st-line EGFRm NSCLC with MET overexpression.
-
Benefit Across MET Subgroups
PFS benefit was shown in both high MET (IHC 3+) and ITT (IHC 2+, IHC 3+) populations, with 326 patients randomized 1:1.
-
Encouraging Overall Survival Trend
The combination showed very encouraging clinical benefit in overall survival, a secondary endpoint; the trial will continue follow-up.
-
Regulatory Path in China
Data will be shared with regulatory authorities to support the 1st-line indication in China, where the combination is already approved for post-progression use.
Analysis · AZN · Life Sciences
The SANOVO Phase III trial met its primary endpoint, showing a statistically significant and clinically meaningful improvement in progression-free survival for the Tagrisso plus Orpathys combination versus Tagrisso alone in treatment-naïve patients with EGFR-mutated NSCLC and MET overexpression. This extends the combination's evidence base into the 1st-line setting in China, building on the prior SAFFRON and SACHI trials in pre-treated patients. The PFS benefit was seen in both the high MET (IHC 3+) and ITT populations, with encouraging overall survival trends. For AstraZeneca, this reinforces Tagrisso as the backbone therapy across EGFRm lung cancer and supports regulatory submissions in China for the 1st-line indication.
How filings like this one have moved
In the 30 days to Oct 5, 2026, 36.9% of the 964 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.65%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, AZN was trading at $161.33 on NYSE in the Life Sciences sector, with a market capitalization of approximately $251.4B. The 52-week trading range was $146.10 to $212.71. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.